General Motors has announced a new round of production stoppages for its North American facilities as a result of the ongoing global microchip shortage. Numerous GM models are impacted, including the Chevy Traverse and Buick Enclave crossovers.
Per a recent report from Reuters, General Motors recently announced that it will extend production downtime at its Lansing Delta Township facility in Michigan by two weeks. As such, production of the Chevy Traverse and Buick Enclave is not expected to resume until September 20th at the earliest.
Further production cuts were also announced at the GM Spring Hill facility in Tennessee, the GM Wentzville facility in Missouri, the GM Fort Wayne facility in Indiana, the San Luis Potosí facility in Mexico, the Silao facility in Mexico, the CAMI Assembly facility in Canada, and the Ramos Arizpe facility in Mexico. In total, GM recently announced new production stoppages at eight of its North American facilities.
In addition to production cuts for the Chevy Traverse and Buick Enclave crossovers, the latest round of production cuts will also affect production of the Cadillac XT5, Cadillac XT6 and GMC Acadia, Chevy Equinox and GMC Terrain, and Chevy Colorado and GMC Canyon, among others.
Like the broader automotive industry, General Motors has faced numerous production stoppages throughout the 2021 calendar year as a result of the global microchip shortage. In order to combat the effects of the shortage, General Motors has employed several different strategies, including something known as a “build-shy” strategy. Essentially, GM’s build-shy strategy is designed to keep production moving by building vehicles in an incomplete state, then parking said vehicles as new microchips are located. Once additional microchips are found, the vehicles are completed and shipped to dealers.
General Motors has also elected to delete certain features that require microchips from its more-popular models, including Dynamic Fuel Management and Active Fuel Management from the Chevy Silverado and GMC Sierra.
Current predictions estimate that the effects of the microchip shortage may last into the 2023 calendar year.